Statins in dermatology: Is nonmelanoma skin cancer the dark side of the moon?

International Journal of Dermatology

Volumn 52, Issue 7, 2013, Pages 899-900

  Mascitelli, Luca ^a   Goldstein, Mark R ^b  

^a Medical Service ^*  (Italy)

^b NCH Healthcare Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; PRAVASTATIN; TRANSCRIPTION FACTOR FOXP3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CANCER MORTALITY; CANCER RISK; CD4+ CD25+ T LYMPHOCYTE; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; NON MELANOMA SKIN CANCER; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; HEALTH SURVEY; SKIN NEOPLASMS;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; POPULATION SURVEILLANCE; SKIN NEOPLASMS;

EID: 84879798976     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05067.x     Document Type: Article

References (10)

1. Goldstein MR, Mascitelli L, Pezzetta F. The double-edged sword of statin immunomodulation. Int J Cardiol 2009; 135: 128-130.
2. Jowkar F, Namazi MR. Statins in dermatology. Int J Dermatol 2010; 49: 1235-1243.
3. Mausner-Fainberg K, Luboshits G, Mor A, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis 2008; 197: 829-839.
4. Raemer PC, Kohl K, Watzl C. Statins inhibit NK-cell cytotoxicity by interfering with LFA-1-mediated conjugate formation. Eur J Immunol 2009; 39: 1456-1465.
5. The PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
6. The Treating to New Targets Study Steering Committee and Investigators. Outcomes of using high- or low-dose atorvastatin in patients 65 years or older with stable coronary heart disease. Ann Intern Med 2007; 147: 1-9.
7. Carroll RP, Segundo DS, Hollowood K, et al. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J Am Soc Nephrol 2010; 21: 713-722.
8. Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer 2008; 44: 2122-2132.
9. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
10. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.